Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation-arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling by Amyere, Mustapha et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
Germline loss-of-function mutations in EPHB4 cause a second form of
capillary malformation-arteriovenous malformation (CM-AVM2)
deregulating RAS-MAPK signaling
Amyere, Mustapha; Revencu, Nicole; Helaers, Raphaël; Pairet, Eleonore; Baselga, Eulalia; Cordisco,
Maria; Chung, Wendy; Dubois, Josée; Lacour, Jean-Philippe; Martorell, Loreto; Mazereeuw-Hautier,
Juliette; Pyeritz, Reed E; Amor, David J; Bisdorff, Annouk; Blei, Francine; Bombei, Hannah;
Dompmartin, Anne; Brooks, David; Dupont, Juliette; González-Enseñat, Maria Antonia; Frieden, Ilona;
Gérard, Marion; Kvarnung, Malin; Hanson-Kahn, Andrea Kwan; Hudgins, Louanne; Léauté-Labrèze,
Christine; McCuaig, Catherine; Metry, Denise; Parent, Philippe; Paul, Carle; Weibel, Lisa; et al;
Vikkula, Miikka
Abstract: BACKGROUND: Most arteriovenous malformations (AVMs) are localized and occur spo-
radically. However, they also can be multifocal in autosomal-dominant disorders, such as hereditary
hemorrhagic telangiectasia and capillary malformation (CM)-AVM. Previously, we identified RASA1
mutations in 50% of patients with CM-AVM. Herein we studied non-RASA1 patients to further elucidate
the pathogenicity of CMs and AVMs. METHODS: We conducted a genome-wide linkage study on a
CM-AVM family. Whole-exome sequencing was also performed on 9 unrelated CM-AVM families. We
identified a candidate gene and screened it in a large series of patients. The influence of several missense
variants on protein function was also studied in vitro. RESULTS: We found evidence for linkage in 2 loci.
Whole-exome sequencing data unraveled 4 distinct damaging variants in EPHB4 in 5 families that coseg-
regated with CM-AVM. Overall, screening of EPHB4 detected 47 distinct mutations in 54 index patients:
27 led to a premature stop codon or splice-site alteration, suggesting loss of function. The other 20 are
nonsynonymous variants that result in amino acid substitutions. In vitro expression of several mutations
confirmed loss of function of EPHB4. The clinical features included multifocal CMs, telangiectasias, and
AVMs. CONCLUSIONS: We found EPHB4 mutations in patients with multifocal CMs associated with
AVMs. The phenotype, CM-AVM2, mimics RASA1-related CM-AVM1 and also hereditary hemorrhagic
telangiectasia. RASA1-encoded p120RASGAP is a direct effector of EPHB4. Our data highlight the
pathogenetic importance of this interaction and indicts EPHB4-RAS-ERK signaling pathway as a major
cause for AVMs.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026886
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-144457
Accepted Version
Originally published at:
Amyere, Mustapha; Revencu, Nicole; Helaers, Raphaël; Pairet, Eleonore; Baselga, Eulalia; Cordisco,
Maria; Chung, Wendy; Dubois, Josée; Lacour, Jean-Philippe; Martorell, Loreto; Mazereeuw-Hautier,
Juliette; Pyeritz, Reed E; Amor, David J; Bisdorff, Annouk; Blei, Francine; Bombei, Hannah; Domp-
martin, Anne; Brooks, David; Dupont, Juliette; González-Enseñat, Maria Antonia; Frieden, Ilona;
Gérard, Marion; Kvarnung, Malin; Hanson-Kahn, Andrea Kwan; Hudgins, Louanne; Léauté-Labrèze,
Christine; McCuaig, Catherine; Metry, Denise; Parent, Philippe; Paul, Carle; Weibel, Lisa; et al;
Vikkula, Miikka (2017). Germline loss-of-function mutations in EPHB4 cause a second form of capillary
malformation-arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling. Circulation,
136(11):1037-1048.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.026886
2
10.1161/CIRCULATIONAHA.116.026886
1
Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of 
Capillary Malformation–Arteriovenous Malformation (CM-AVM2) 
Deregulating RAS-MAPK Signaling
Running Title: Amyere et al.; Loss-of-Function Mutations in EPHB4 Causes CM-AVM2
Mustapha Amyere, PhD & Nicole Revencu, MD, PhD, et al.
The full author list is available on page 14
Address for Correspondence:
Miikka Vikkula, MD, PhD
de Duve Institute 
Université Catholique de Louvain 
Human Molecular Genetics
Avenue Hippocrate 74
B-1200 Brussels Belgium
Tel: + 32-2-764 7490
Fax: + 32-2-764 7460
Email: Miikka.vikkula@uclouvain.be
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.116.026886
2
Abstract
Background—Most AVMs are localized and occur sporadically; however they also can be 
multifocal in autosomal dominant disorders, such as Hereditary Hemorrhagic Telangiectasia 
(HHT) and Capillary Malformation–Arteriovenous Malformation (CM-AVM). Previously, we 
identified RASA1 mutations in 50% of patients with CM-AVM. Herein we studied non-RASA1 
patients to further elucidate the pathogenicity of CMs and AVMs.
Methods—We conducted a genome-wide linkage study on a CM-AVM family. Whole exome 
sequencing was also performed on 9 unrelated CM-AVM families. We identified a candidate-
gene and screened it in a large series of patients. The influence of several missense variants on 
protein function was also studied in vitro.
Results—We found evidence for linkage in two loci. Whole-exome sequencing data unraveled 
four distinct damaging variants in EPHB4 in five families that co-segregated with CM-AVM. 
Overall, screening of EPHB4 detected 47 distinct mutations in 54 index patients: 27 lead to a 
premature stop codon or splice-site alteration, suggesting loss of function. The other 20 are non-
synonymous variants that result in amino-acid substitutions. In vitro expression of several 
mutations confirmed loss of function of EPHB4. The clinical features included multifocal CMs, 
telangiectasias, and AVMs. 
Conclusions—We found EPHB4 mutations in patients with multifocal CMs associated with 
AVMs. The phenotype, CM-AVM2, mimics RASA1-related CM-AVM1 and also HHT. RASA1
encoded p120RASGAP is a direct effector of EPHB4. Our data highlights the pathogenetic 
importance of this interaction and indicts EPHB4-RAS-ERK signaling pathway as a major cause 
for arterio-venous malformations.
Key Words: arteriovenous malformation; arteriovenous fistula; capillaries; cardiovascular 
disease; vascular disease; 
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Clinical Perspective 
What is new? 
? Identification of a second type of capillary malformation-arteriovenous malformation 
(CM-AVM), named CM-AVM2.
? CM-AVM2 is characterized by intra/extra-cranial AVMs, multifocal CMs and 
telangiectasias.
? CM-AVM2 mimics RASA1-mutated CM-AVM1, but also hereditary hemorrhagic
telangiectasia (HHT).
? Prevalence of CM-AVM1/2 is similar to that of HHT.
? CM-AVM2 is inherited as an autosomal dominant disorder.
? CM-AVM2 is caused by loss-of-function mutations in EPHB4.
? AVMs are caused by dysregulation of EPHB4-p120RASGAP (RASA1) interaction and 
downstream RAS-MAPK signaling.
What are the clinical implications? 
? Patients with multifocal CMs need to be screened not only for an inherited RASA1 
mutation, but also for EPHB4. 
? Presence of telangiectasias may cause confusion with HHT.
? Screening of EPHB4 in HHT patients without a mutation in one of the 4 HHT genes and 
in patients with hereditary benign telangiectasia is to be considered to improve 
diagnostic.
? Risk for an intra-central system fast-flow lesion is lower than in CM-AVM1, but follow-
up is needed.
? Inhibitors of EPHB4-p120RASGAP downstream signaling effectors, such as RAS and 
ERK, should be evaluated as possible molecular therapies for the management of AVM 
and CM.
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Fast-flow lesions are characterized by direct communications between arteries and veins without 
an intervening normal capillary bed. In arteriovenous malformations (AVM), the arterial blood is 
shunted from the feeding arteries into the draining veins via a bundle of abnormal vessels, called 
the nidus. These lesions are usually congenital. Arteriovenous fistula (AVF) is another variant, in 
which communication between an artery and vein is direct, often caused by trauma. Multiple 
micro-AVFs are seen in Parkes Weber syndrome, in association with soft tissue and skeletal 
hypertrophy of the affected limb (OMIM 608355)1.
AVMs can occur anywhere in the body; the central nervous system is the most common 
location. Symptoms depend on the site and age of the patient; e.g., fetal hydrops, cardiac failure, 
epilepsy and focal neurological deficit.2 Progressive vascular dilation, potentially leads to rupture 
and hemorrhage.3 AVMs are one of the most difficult to treat vascular anomalies and are
associated with high morbidity and mortality.2, 4, 5 They are highly dynamic with features of 
invasive growth, aggravation after incomplete resection, and regrowth even after clinically 
complete surgical removal.6
AVM can occur as an isolated feature or as part of a syndrome; the most common are
hereditary hemorrhagic telangiectasia (HHT) and capillary malformation - arteriovenous 
malformation (CM-AVM). 7-10 HHT or Osler-Weber-Rendu syndrome (MIM187300) is a well-
known autosomal dominant, genetically heterogeneous disorder, characterized by AVMs, 
typically in liver and lung, in association with cutaneous and mucosal telangiectasias. CM-AVM 
(MIM608354) is an autosomal dominant disorder with high penetrance and variable 
expressivity.8 These patients have small multifocal cutaneous capillary malformations (CMs).9-11
AVMs are seen in about 30% of the patients and are typically located in brain, spinal cord, face, 
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neck or extremities.9, 10, 12 Parkes Weber syndrome is included in this disorder.10 CM-AVM 
patients do not have frequent epistaxis, the hallmark of HHT.3, 7, 12
About one-half of the patients with CM-AVM have heterozygous loss-of-function 
mutations in RASA1.9, 10 This gene encodes the cytoplasmic P120RASGAP protein, a negative 
regulator of the RAS signal transduction pathway that enhances the weak intrinsic GTPase 
activity of normal RAS p21.13 P120RASGAP plays an important role in vascular development 
during murine embryogenesis13, 14. We studied several families that have phenotypical CM-AVM 
but without a RASA1 mutation. Our hypothesis was that additional genes might be involved; we 
used linkage and whole exome sequencing to further unravel the pathogenetic cause of this 
disorder. 
Methods
Recruitment of Patients 
From our database of patients with vascular malformations, collected in our long-active research 
project, we culled 365 index individuals. Inclusion criteria were sporadic or familial CMs 
associated or not with fast-flow vascular malformations. All the participants or their legal 
guardians gave informed consent for the participation in the study. The ethnicity of the patients 
with an identified mutation (n=54) varied: Caucasian: 42, Hispanic: 7, North African: 3, 
Japanese: 1 and Chinese: 1. The research protocol was approved by the ethical committee of the 
medical faculty at Université catholique de Louvain, Brussels, Belgium. 
Linkage Analysis 
Molecular karyotyping was performed in all samples with Affymetrix
Human Mapping 250K NspI according to the manufacturer’s (Affymetrix) instructions 
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(Supplementary Methods). Genome-wide parametric multipoint linkage was performed using 
Merlin program12 in a large family with CM-AVM that did not have a RASA1 point mutation or 
genomic rearrangement (CM-13-HO; Supplementary Figure 1). The parametric analyses were 
run under an autosomal dominant model, assuming a penetrance of 90% and 1% phenocopy rate. 
Haplotype reconstruction was used to exclude RASA1 and to confirm segregation of the 
chromosome 7 locus with the CM-AVM phenotype in this family. 
High Throughput Sequencing 
Genomic DNA for one affected CM-13-HO family member and 10 patients from 8 additional 
families were used for whole exome sequencing. Exons were captured with Agilent 
SureSelectXT Human All Exon kit and sequenced with an Illumina HiSeq2000. We designed a
custom AmpliSeq panel to sequence all exons and exon-intron boundaries of RASA1 and EPHB4
using the Ion PGM™ Sequencer. Called variants were annotated, filtered and visualized using 
Highlander, an in-house bioinformatics framework (Helaers and Vikkula, submitted; see URLs). 
Our sequencing methods, as well as variant filtering procedures, are described in the 
Supplementary Methods.
Effect of Non-Synonymous Variants on EPHB4 Function 
Disease-causing variants were introduced in EGFP-EPHB4 cDNA by site directed mutagenesis 
and transiently expressed in COS-7 cells. Stability of EPHB4 was accessed by Western blotting 
in cells treated or not with lysosome (Chloroquine) or proteasome inhibitors (MG132). 
Subcellular localization of EGFP-EPHB4 was evaluated by fluorescence imaging. 
Statistical Analysis 
To distinguish pathogenic mutations from background polymorphisms we evaluated the 
distribution of rare non-synonymous variants (NSVs) within the two genes, EPHB4 and RASA1. 
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Only NSVs with maximum allele frequency <0.003 in seven public databases (ExAC_af, 
1000G_AF, ESP6500_AA_AF, ESP6500_EA_AF, gonl_af, ARIC5606_AA_AF and 
ARIC5606_EA_AF) were retained for analyses. NSVs were classified into tolerated or damaging 
on the basis of their aggregation score, as defined by Dong and coworkers.15 These scores are 
based on nine prediction algorithms (SIFT, PolyPhen-2, GERP++, Mutation Taster, Mutation 
Assessor, FATHMM, LRT, SiPhy, PhyloP), the maximum frequency observed in the 1000 
genomes database, and pre-computed with Logistic Regression (LR) for 87 347 044 possible 
variants in the entire human exome. Frequencies of tolerated (aggregation score: 0 - 0.49) and 
damaging (aggregation score: 0.5 - 1) NSVs in RASA1 and EPHB4 genes were compared 
between our patient cohort and control population on the basis of the largest public database 
ExAC16 (60.706 unrelated whole exomes). As our study group consisted mainly of Caucasians 
(79,6%), we excluded individuals of other ethnicities from this analysis. Enrichment was 
estimated by Pearson’s chi-square test: 2-sample test for equality of proportions with continuity 
correction (R-package v3.1.2).17
Results 
Identification of EPHB4 As the Mutated Gene
The genome-wide linkage analysis conducted with CM-13-HO family (supplementary Fig.1A)
showed two noteworthy peaks with maximum LOD-scores of 2.5 and 2.8 on chromosomes 5 and 
7, spanning 74.2 Mb and 59.1 Mb, respectively (supplementary Fig.1B-C). Whole exome 
sequencing revealed 4 damaging variants in 5 families in a single gene, EPHB4 (supplementary 
Table 1). Subsequent targeted gene sequencing identified 47 distinct mutations in 54 index 
patients out of 365 sequenced: 9 were non-sense, 11 caused a frame-shift, and 7 altered a
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consensus splice site. These 27 mutations suggested loss-of-function of EPHB4. Twenty variants
lead to amino-acid substitutions predicted to alter protein function (Fig. 1 and Table 1). The
mutations co-segregated with the phenotype in each family (supplementary Fig.2). A splicing 
defect was confirmed in mRNA for 2 variants in subjects for whom lymphoblasts were available.
Moreover, the frequency of rare damaging non-synonymous variants (NSV) was significantly 
different between our study group and the large Exome Aggregation Consortium (ExAC) 
dataset; (p-value < 0.0001; supplementary Fig.3). This was not seen for RASA1, mutations in 
which are known to be STOP-gains, Indels or splice-site changes. The data fulfill all the criteria 
set up by MacArthur and colleagues on reporting on causality of sequence variants in newly
identified genes.18
The identified mutations are scattered along EPHB4 (Fig. 1). As the most 5-prime 
premature STOP codon appears at amino acid position 12, there is a low likelihood for 
neomorphic or dominant-negative function. There was no genotype-phenotype correlation
according to position or type of mutation. Thus, all mutations should lead to haploinsufficiency. 
In one family, the c.345_347delCTA mutation deleted a tyrosine-(115) in the EphrinB2 binding 
domain, suggesting that this interaction may be particularly important for EPHB4-EphrinB2 
signaling (Fig. 1). Further evidence is a study of crystal structure of the ligand binding domain of 
EPHB4 in complex with the extracellular domain of ephrinB219. Yet, several missense mutations
(n=9/20) clustered within the catalytic domain of EPHB4, encoded by exons 14 and 15. We 
expressed four of them (p.E664K; p.C845R; p.R838W and p.R864W) and detected low level of
mutant forms compared to the wild type (Fig. 2A). Inhibition of endosome-lysosome 
acidification stabilized EPHB4 expression, bringing it close to wild-type levels, whereas 
inhibition of proteasomal system had a very weak effect (Fig. 2A). The same effect was 
 by guest on July 8, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
10.1161/CIRCULATIONAHA.116.026886
9
observed when the two treatments were combined with protein synthesis inhibitors (data not 
shown). The typical membranous staining of EPHB4 (Fig. 2A) was not seen with mutant forms 
by immunofluorescence. Fluorescent vesicular inclusions without EPHB4 are detected only in
mutant (Fig. 2 C-F). In summary, these findings underscore that the mutations induce loss of
function of EPHB4.
Identification of Mutations in EPHB4 Allowed Clinical Characterization of a New Entity: 
CM-AVM2
We analyzed clinical data from the 110 individuals (54 index patients and 56 relatives) found to 
have an EPHB4 mutation. Penetrance was high, 93% (n=102). Isolated multifocal CMs were 
identified in 34 families (63%). In the remaining 19 families (35%) at least one individual had an 
AVM in addition to CMs (Table 1). All affected subjects (n=102) had pink-to-red cutaneous 
CMs, usually multifocal; 10 patients had only one CM. About 25% of the CMs had a 
surrounding white halo believed to be caused by micro-AV-shunting as detected by to-fro 
murmur with a Hand-held Doppler instrument (Fig. 3). CMs were either present at birth or 
appeared later during childhood or adolescence, and were localized on the extremities, trunk or 
head and neck. Size varied from pinpoint to large lesions, up to 15 cm in diameter; the borders 
were usually geographic. The stains were homogenous or telangiectatic, sometime with a pale 
central zone. Bier spots were noted in 13 individuals (12%), and 16 (15%) had telangiectasias, 
especially on upper thorax and lips, or periorally. Only a few patients had recurrent epistaxis. 
Fast-flow lesions were present in 20 individuals (18%): arteriovenous fistulae (AVF; 
n=1), AVM (n=12), and Parkes Weber syndrome (n=8) (Fig. 3). Three lesions were located in
the central nervous system: vein of Galen aneurysmal malformations (n=2) and intraspinal 
arteriovenous fistula (n=1). One additional vein of Galen aneurysmal malformation was 
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identified in a fetus whose father carried an EPHB4 mutation, but fetal DNA was not available
for analysis. The other AVMs were located in the face (n=8), and the extremities (n=1). One 
patient had 2 AVMs. The eight Parkes Weber lesions were located in the right arm (n=2), left 
arm (n=2), right leg (n=3) and left leg (n=1)(Table 1).
Discussion 
In this study, we identified EPHB4 as a second gene that is mutated in patients with capillary 
malformation-arteriovenous malformation. We propose to name this entity CM-AVM2 to 
differentiate it from CM-AVM1 caused by RASA1 mutations. These vascular disorders have 
similar characteristics, but there are also differences, which are important for differential 
diagnosis. Both are characterized by multifocal CMs and increased risk for fast-flow vascular 
malformations. The CMs are usually small with a haphazard distribution. Bier spots are observed 
in both conditions, but are more frequent in CM-AVM2. Moreover, the large CMs in CM-AVM2 
can have a pale central region. Telangiectasias, especially obvious on the lips, but also in the 
perioral region and on the upper thorax, are seen in CM-AVM2, but not in CM-AVM1.
Fast-flow vascular malformations occur in CM-AVM2 and in CM-AVM1; however, the
overall risk is somewhat lower in CM-AVM2 (18% versus 31%). The frequency of Parkes 
Weber syndrome and cervico-facial AVM is the same between the two entities, 7%.9, 10 In 
contrast, AVMs in the central nervous system were found in 3% of patients with CM-AVM2,
compared to 10% of patients with CM-AVM1.9, 10, 12 Of note, the 2 intracranial AVMs diagnosed 
in CM-AVM2 were vein of Galen aneurysmal malformations; another vein of Galen anomaly
was diagnosed in utero. Thus, EPHB4 is a supplementary gene to be considered in patients with 
this dangerous intracranial fast-flow lesion, often first detected prenatally.
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Telangiectasias are a major feature of both HHT and Hereditary Benign Telangiectasia 
(HBT). They can cause confusion with CM-AVM2. HHT is a well-known autosomal dominant,
genetically heterogeneous disorder with 4 causative genes identified and at least two other loci
awaiting elucidation.7, 20,21, 22 HBT is a rare autosomal dominant disorder of unknown etiology
and characterized by widespread cutaneous telangiectasias. In contrast to HHT, these patients 
have neither epistaxis nor fast-flow vascular malformations.20, 23-25 . The concurrence of CMs 
with telangiectasias in CM-AVM2 is a major clinical clue to differentiate it from HHT and HBT. 
In addition, the extra central nervous system fast-flow vascular malformations are different in 
CM-AVM2 from those in HHT. CM-AVM2 is associated with cutaneous, subcutaneous,
muscular and bony AVMs in face and neck or extremities and Parkes Weber syndrome, whereas 
pulmonary and hepatic AVMs occur in HHT. Since not all HHT patients have pulmonary and/or 
hepatic AVMs, sequencing EPHB4 in those without a mutation in one of the 4 HHT genes is
indicated. It would also be interesting to test EPHB4 in patients with HBT, as all the features in
this disorder are observed in patients with CM-AVM2.
The prevalence of HHT is reported to be 1/5,00026. The Exome Aggregation Consortium 
(ExAC) dataset includes 10 loss-of-function mutations (premature STOP codons or strong splice 
site mutations) in 60,706 subjects, a prevalence of 1/6,000. Similar mutations are present 3 times 
in RASA1 and 5 times in EPHB4; thus prevalence estimates are 1/20,000 and 1/12,000,
respectively. This calculation ignores all pathogenic amino acid substitutions. Overall, the
prevalence of CM-AVM1/2 is similar to that of HHT1/2/3; and CM-AVM subtypes are strongly 
under-diagnosed.
Mutations in EPHB4 were identified in 54 families. Most mutations were private to each 
affected family except for five mutations, which occurred in two families and one which 
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occurred in three families. The mutations are located throughout the gene; we found no
genotype-phenotype correlations. The localized nature and multifocality of lesions in CM-
AVM2 can be explained by the need for a somatic second hit for complete cellular abolishment 
of EPHB4 function. This two-hit phenomenon has been shown for other hereditary multifocal 
vascular malformations, such as CM-AVM1, glomuvenous malformations (GVM; OMIM 
138000) and cutaneomucosal venous malformation (VMCM, OMIM 600195) 10, 27, 28,29. The 
inherited mutation can be considered as a predisposing event, whereas additional genetic 
alterations disturb cellular function. No mutation was identified in 311 index patients. This 
negative finding was not unexpected taking into consideration the heterogeneity of our cohort, 
which includes patients with sporadic or familial CMs with/without a fast-flow vascular 
malformation. Moreover, regulatory regions were not analyzed.
The mechanism leading to CMs and AVMs in CM-AVM2 is likely a loss-of function of
EPHB4. The majority of the mutations generate a premature stop codon, frame-shift or splice-
site alteration (57%), leading to non-sense-mediated mRNA decay or an unstable and/or 
truncated protein. Moreover, our functional studies on several missense mutations, enriched in 
the catalytic domain of EPHB4, have shown reduced expression of mutant protein, caused by 
lysosomal degradation. As other inherited multifocal vascular anomalies have somatic second-
hits, it is likely that the endothelial cells that drive formation of the lesions in CM-AVM2 are 
completely devoid of EPHB4 function. Unfortunately, we did not have tissue available to study 
this.
EPHB4 is a transmembrane receptor that is preferentially expressed in venous endothelial
cells during vascular development.30, 31 Its ligand, EphrinB2, is also a transmembrane protein, 
which is expressed in arterial endothelial cells.32 This bidirectional signaling system, in concert 
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with Notch signaling, is a major controller of arterial-venous differentiation, especially via the 
forward signaling of EPHB4.33,34 Coordinated activation of the two proteins is essential for 
establishment of venous and arterial endothelial identity and corresponding vessel formation (Fig 
4).33,34 EphB4-/- mice, as well as ephrin-B2-/- mice30, 35, die at embryonic day E10.5, as a 
consequence of defects in peripheral angiogenesis, establishment of arteriovenous boundaries
and vascular remodeling.32
EPHB4 signals via RAS/MAPK/ERK1/2 and PI3K/AKT/mTORC1 pathways.36 In 
zebrafish, inhibition of EPHB4 or p120RasGap causes very similar vascular defects.37 Moreover, 
EPHB4 with mutated conserved juxtamembrane tyrosine residues, abrogates the interaction with 
p120RASGAP, demonstrating that it is a pivotal effector of EPHB4 signaling.38 The phenotypic 
similarity of CM-AVM1 and CM-AVM2 underscores this functional link, and incriminates 
dysregulation in EPHB4 signaling pathway as the cause of CM and AVM. Consequently, RAS 
and its downstream effectors, RAS/MAPK/ERK1/2 and PI3K/AKT/mTORC1, are constitutively
activated (Fig. 4). ERK activation was observed in tissue samples from patients with RASA1
mutation.37 Moreover, single somatic activating GNAQ/GNA11 mutations in sporadic CMs also 
activate these pathways.39, 40 Thus, sporadic AVMs are likely caused by somatic activating 
mutations in (a) key molecule(s) of this signaling pathway as recently reported for 16 out of 25
patients with an extracranial sporadic AVM.41
The annual risk of hemorrhage associated with brain AVMs is about 2% per year.42 The 
Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) concluded that 
medical management is superior to endovascular interventional therapy alone for the prevention 
of death and stroke.42 Extra-cranial AVMs present an equal therapeutic dilemma, with early 
complete surgical resection with/without embolization being the only hope for long-term 
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control.43 Inhibitors of EPHB4-p120RASGAP downstream signaling effectors, such as RAS and 
ERK, should be evaluated as possible therapy for AVM, and CM.
In conclusion, we identified a hitherto unrecognized clinical entity, similar in clinical 
presentation to CM-AVM1 and, thus named CM-AVM2. Cutaneous CMs are highly penetrant 
and are associated with AVMs. Telangiectasias and epistaxis also occur, placing this novel 
disorder phenotypically between CM-AVM1 and HHT. The distribution of AVMs is more 
similar to CM-AVM1. CM-AVM2 is caused by loss-of-function mutations in EPHB4, whereas 
CM-AVM1 is due to loss-of-function of p120RASGAP. The latter has been demonstrated to be a
direct effector of EPHB4. Our data highlights the pathogenetic importance of this interaction and 
indicts EPHB4-RAS-ERK signaling pathway as a major cause for CMs and AVMs. Modulating 
activity of the EPHB4-RAS-ERK pathway would be a novel therapeutic strategy.
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Table 1. 54 families with EPHB4 mutations and corresponding clinical features
D of screened 
patient 
hgvs 
DNA
hgvs 
protein
Consensus
prediction
Number of 
mutation carriers
Number of 
patients with
CM
Location of 
AVM
Location of
Parkes 
Weber 
Syndrome
ExAC
allele
frequency
CM-13-HO-II-6Ac.33delG p.L12Wfs*10 40 7 7 0 0
CM-565-10 c.123+3G>C; r.123_411del p.W18Vfs*16 20 4 3 0 0
CM-415-10 c.175G>A p.E59K 4 1 1 0 left arm 
CM-184-10 c.221G>C p.R74P 4 2 2 0 0
CM-177-10 c.389G>A p.W130* 42 1(‡) 1 0 0
CM-219-10 c.412-1G>T 33 4 3 0 0
CM-378-10 c.447_448insGAAG p.R150Efs*74 40 3 2 0 0
CM-348-10 c.481_485delGTCAAinsTTp.V161_K162delinsL 10 1 (†) 1 0 0
CM-115-100 c.560T>C p.L187P 5 1 1 0 left leg
CM-291-10 c.632_633delTG p.V211Afs*11 40 2 2 0 0
CM-568-10 c.730C>T p.Q244* 43 3 3 0 0
CM-90-10 c.802T>C p.C268R 6 4 4 0 right leg
M-302-10 c.345_347delCTA p.Y115del 10 1 1 right face 0
CM-455-10 c.1054C>T p.R352* 42 1 (‡) 1 0 0
CM-558-10 c.1054C>T p.R352* 42 2 2 0 0
CM-546-2 c.1077_1081delCCGCT p.L359fs*19 40 2 2 0 0
CM-337-106 c.1123G>T p.Gly375* 41 3 3 0 0
CM-345-10 c.1177_1177delG p.V393Ffs*17 40 1 1 0 0
CM-391-100 c.1291C>T p.R431* 42 3 3 0 0 0.00001
CM-377-10 c.1406T>G p.V469G 5 4 4 0 0
CM-120-10 c.1423-6G>A; r.1422_1423insACAG p.G475Tfs*39 22 4 3 0 0
CM-147-100 c.1546G>A p.G516R 5 2 1 left face and lip 0 0.00002
CM-162-100 c.1546G>A p.G516R 5 1 1 left face 0
CM-538-10 c.1546G>A p.G516R 5 2 2 0 0
CM-487-10 c.1558C>T p.Gln520* 41 1 1 0 0
CM-544-10 c.1558C>T p.Gln520* 41 1 1 0 0
CM-470-10 c.1588+5G>C 22 1(†) 1 0 right arm
CM-323-10 c.1615delG p.A539fs*2 40 3 3 0 right leg
CM-131-101 c.1692-1G>A 33 1 (†) 1 0 0
CM-401-10 c.1733_1734insA p.G579Rfs*10 40 2 2 0 0
CM-224-11 c.1788T>G p.Y596* 42 2 2 0 left arm
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CM-239-10 c.1870+2T>C 33 2 1 left face 0
CM-298-10 c.1966C>T p.R656W 5 1 1 0 0
CM-397-10 c.1990G>A p.E664K 6 4 3 VGAM/VGAM 0
CM-105-11 c.2037_2038insT p.E680* 40 2 2 left arm right leg
CM-340-10 c.2173G>A p.A725T 6 1 (†) 1 0 0
CM-459-10-1 c.2215C>T p.R739* 41 2 2 0 0 0.00002
CM-74-II-1 c.2215C>T p.R739* 41 1 1 0 0 0.00002
CM-297-2 c.2233A>G p.N745D 6 1 (†) 1 0 0
CM-433-11 c.2233A>G p.N745D 6 4 4 0 right arm
CM-236-10 c.2365C>T p.P789S 6 2 1 left face 0
CM-324-10 c.2366C>G p.P789R 6 2 2 0 0
CM-488-10 c.2379delC p.A793fs*16 40 1 1 0 0
CM-498-10 c.2418C>G p.Y806* 42 3 3 0 0
CM-373-10 c.2419G>A p.G807R 6 2 2 left ear 0
CM-407-2 c.2458C>A p.P820T 6 2 2 0 0
CM-567-10 c.2459C>T p.P820L 6 3 3 lips 0
CM-490-10 c.2484+1G>A 33 1 1 D8-L1 perimedullar AVF 0
CM-444-10 c.2512C>T p.R838W 6 1 1 0 0 0.00001
CM-282-10 c.2533T>C p.C845R 6 1 1 face and upper lip 0
CM-426-10 c.2567G>A p.C856Y 6 1 (‡) 1 0 0
CM-110-101 c.2590C>T p.R864W 6 1 (†) 1 0 0
CM-390-10 c.2590C>T p.R864W 6 2 2 0 0
CM-157-10 c.2621T>C p.L874P 6 1 (†) 1 left face 0
hgvs = Annotation based on Human Genome Variation Society; Consensus prediction = Functional predictions retrieved from dbNSFP4.1 (damaging in SIFT, 
deleterious in LRT, high or medium in Mutation Assessor, damaging in Fathmm, disease-causing in Mutation Taster, and a score > 0.5 in Polyphen2); ExAC =  Exome 
Aggregation Consortium. 
Consensus prediction column gives the number of different algorithms that suggest a variant to be damaging. The maximum is 6 for missense variants, as six different 
algorithms are used (Sift, LRT, Mutation Assessor, FATHMM, Mutation Taster and Polyphen2). In addition, if the variant affects splicing (evaluated by two distinct 
algorithms: ada and rf), +1 or +2 is added. Furthermore, to better distinguish variants with high potential for deleterious effects, +10 is added for variants that cause a 
loss of a start or stop-codon, or insertion or deletion of a codon with or without codon change. +20 is added for variants in splice site regions, and +30 for variants in 
consensus splice sites and for small exon deletions. +40 is added for variants causing a frame shift or appearance of a premature STOP codon.
VGAM : vein of Galen aneurysmal malformation; VGAM/VGAM : 2 affected individuals in the same family; (*) Non-sense mutation position in protein. (†) : DNA not 
available from other affected family members ; (‡) : confirmed sporadic case. 
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Figure Legends
Figure 1. Schematic representation of EPHB4 gene and its protein-coding domains, with 
CM-AVM2-causing mutations. EPHB4 domains: Ephrin-b2 binding domain; cysteine-rich 
domain, two fibronectin (FN) type III domains; transmembrane (TM) region; tyrosine kinase 
domain and SAM domain. Mutations: above, causing premature stops, frame-shifts and splice 
site changes; below: missense substitutions predicted to be damaging. Four expressed mutations 
marked in red.
Figure 2. Missense mutations in EPHB4 from 4 CM-AVM2 patients lead to proteosomal 
degradation. COS7 cells are transiently transfected with EGFP-EPHB4 wild type EPHB4 or
with one of the 4 mutations. Evaluation of ubiquitination in cells pre-treated with chloroquine or 
MG132 (A). Protein expression accessed by Western Blotting using anti-EPHB4, or monoclonal 
anti-?-actin. Representative experiments of three transfections performed are shown. Confocal 
laser scanning microscopy of cells transiently expressing wild-type EGFP-EPHB4 (B) or the 4 
EGFP-EPHB4-mutants (C-F). Images are representative of 100 analyzed cells from 3 
independent transfections. Arrow indicates EPHB4 ; NT = non-treated ; scale bars = 5 μm.
Figure 3. Phenotypic spectrum associated with EPHB4 mutations. 
Multifocal CMs and Bier spots (A). Multifocal CMs (B). Multifocal CMs with white 
surrounding halo (C). Multiple telangiectasias on upper thorax (D). Multiple labial and 
peribuccal telangiectasias (E). Multifocal CMs with geographic borders and pale central zone
(F). AVM on the face (G). Vein of Galen aneurysmal malformation (H). Parkes Weber 
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syndrome in right leg (I).
Figure 4. Role of EPHB4 in AVM formation.
Artery-fated angioblasts (cell colored in red) express EphrinB2 and inhibit expression of venous 
markers (EPHB4, and Chicken ovalbumin upstream promoter transcription factor II, COUP-
TFII). Venous fated ECs (cell colored in blue), express COUP-TFII and thereby the EphrinB2 
receptor EPHB4, and  suppress expression of Notch signaling. EphrinB2/EPHB4 interaction 
responsible for suppression of RAS/MEK/ERK and RAS/AKT/mTORC1 pathways. Lack of 
EPHB4 or p120RASGAP in venous endothelial cells of CM-AVM2 and CM-AVM1 patients, 
respectively (cell colored in light green), results in constitutive activation of RAS/MEK/ERK 
and RAS/AKT/mTORC1 pathways, leading to abnormal differentiation of ECs and disorganized 
vascular development.
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MICROARRAY ANALYSIS. Molecular karyotyping was performed on blood DNA of 1 
15 family members of CM-13-HO with Affymetrix Human Mapping 250K NspI according to the 2 
manufacturer’s (Affymetrix) instructions. In brief, total genomic DNA was digested, and fragments 3 
were ligated to adaptors and amplified with a single primer. After purification of the PCR products, 4 
amplicons were quantified, fragmented, labeled, and hybridized on the array. Signal intensities 5 
were measured with Affymetrix GeneChip Scanner 3000 7G. Genotypes were extracted with 6 
Affymetrix Genotyping Console software 4.1.4. 7 
 8 
EXOME SEQUENCING. Briefly, 1 μg of genomic DNA from 11 blood samples of 9 
patients from 9 unrelated families were processed. Exons were captured using the Agilent 10 
SureSelect Human All Exon V5 and sequenced with an Illumina HiSeq2000 to generate paired-11 
end, 90-bp reads. Image analysis and base calling were performed by sequence control software 12 
real-time analysis and CASAVA software v1.8 (Illumina). Reads were aligned to GRCh37 using 13 
software package for mapping Burrows-Wheeler Aligner (BWA; see URLs). Duplicate reads were 14 
marked using Picard (see URLs) and excluded from downstream analysis. After merging the BAM 15 
files using SAM tools, local realignments around Indels and base quality score recalibration were 16 
performed with the Genome Analysis Toolkit (GATK) v2.8. Single-nucleotide variants and small 17 
Indels were identified using the GATK Unified Genotyper. Called variants were subsequently 18 
annotated, filtered and visualized using Integrative Genome Browser (IGV) and Highlander 19 
software; in-house bioinformatics framework (see URLs). We achieved mean coverage of 54-fold, 20 
with 82% of target covered at least 20x. We focused on non-synonymous variants (NSVs), splice 21 
acceptor and donor-site variants (SSVs), and small insertions/deletions (InDels) that are more 22 
likely to be pathogenic than other variants (supplementary Table 1 and supplementary Table 23 
2). 24 
3 
 
 1 
TARGETED DEEP-SEQUENCING. A custom AmpliSeq panel was designed (20 2 
amplicons; 6.12 Kb) to sequence all exons and exon-intron boundaries of RASA1 and EPHB4 3 
using the Ion PGM™ Sequencer. The whole cohort of 365 index patients was screened. Library 4 
enrichment of target region was amplified using the custom AmpliSeq panel (ThermoFisher), 5 
according to manufacturer's protocols. Briefly, after PCR-based target amplification and digestion 6 
of primer sequences, Ion P1 adaptors and Ion Xpress barcodes were ligated to the amplified 7 
products. The barcoded libraries were purified using the Agencourt AMPure XP kit (Beckman 8 
Coulter Genomics) and washed with 70% ethanol before PCR-based library amplification. 9 
Libraries were quantified using Tapestation (Agilent), and subsequently pooled. Emulsion PCR 10 
was carried out using the Ion PGM Template OT2 200 Kit on OneTouch 2 System (both from 11 
ThermoFisher) according to manufacturer’s protocol. Prepared templates (bead-bound DNAs) 12 
were loaded onto an Ion 316 Chip V2, and sequenced using the Ion PGM Sequencing 200 Kit v2 13 
on an Ion PGM (all from ThermoFisher). Raw sequences (FASTQ files) were separated by bar-14 
code and aligned to the human genome reference sequence (assembly GRCh37/hg19) by the 15 
Torrent Server (ThermoFisher). Aligned sequence (BAM) files were submitted to the Torrent 16 
Variant Caller for variant calling v5.0.3 (ThermoFisher). Called variants were subsequently 17 
annotated, filtered and visualized using Highlander. All variants were filtered against public 18 
databases (dbSNP137, 1000 Genomes and ExAC) and against our own database. We retained 19 
variants causing premature stop-codons, reading frame shifts, consensus splice site alterations 20 
or predicted damaging by at least four softwares. The mutations were subsequently confirmed 21 
and the segregation checked in each family by Sanger sequencing. 22 
 23 
4 
 
EXPRESSION OF WILD TYPE AND MUTANT EPHB4. EGFP-EPHB4 1 
cDNA vector (OriGene) was used to introduce 4 damaging variants (p.E664L; p.C845R; p.R838W 2 
and p.R864W) using the QuikChange Site directed Mutagenesis Kit (Agilent), according to the 3 
manufacturer’s instructions. COS-7 Cells were transiently transfected with jetPEI reagent 4 
(Polyplus Transfection), according to the manufacturer’s guidelines. Cells were pre-treated or not 5 
for 15h, with 50 µM of chloroquine (Sigma), an inhibitor of endosome-lysosome acidification or 6 
with 1 µM of MG132 (Sigma), a proteasome inhibitor. Cells were lysed in lysis buffer (50 mM 7 
HEPES, pH 7.4, 150 mM NaCl, 1% Triton X-100, 5 mM EGTA) buffer containing phosphatase 8 
inhibitors (1 mM sodium orthovanadate and 1 mM NaF) and a proteinase inhibitor cocktail 9 
(Roche). Cell lysates were subjected to immunoblotting to assess protein expression. Antibodies 10 
used were: monoclonal anti--actin (#A5441, Sigma-Aldrich) and rabbit polyclonal anti-EPHB4 11 
(#14960, Cell Signaling Technology, Inc.).  12 
 13 
IMMUNOFLUORESCENCE. COS-7 cells were used to express EGFP-EPHB4 wild 14 
type or each one of the 4 mutants on glass coverslips in six-well plates. After transfection, cells 15 
were washed, fixed with 4% paraformaldehyde, incubated at room temperature for 30 min and 16 
treated with buffer containing 0.1 M glycine in PBS (pH 7.4) and 0.3% Triton X-100. For 17 
fluorescence imaging, Axiovert confocal microscope (Zeiss, Oberkochen, Germany) coupled to a 18 
MRC1024 confocal scanning laser equipment (Bio-Rad, Richmond, CA), was used. 19 
  20 
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 1 
 2 
Supplementary Figure. 1: Linkage study on CM-13-HO.  3 
Pedigree of family (CM-13-HO) used for genome-wide linkage analysis. Numbered subjects were 4 
included for genome-wide SNP-genotyping. Black symbol = affected (a). Result of multipoint 5 
parametric-linkage analysis results for chromosomes 5 (b) and 7 (c). X axis, chromosomal position 6 
in megabases (Mb); y axis, corresponding LOD score. Arrows, RASA1 and EPHB4 locations in 7 
(b) and (c), respectively. 8 
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 1 
Supplementary Figure 2. Four families showing co-2 
segregation of their EPHB4 mutation with CM-AVM2. 3 
* patient screened by whole exome sequencing. ** patient screened by targeted gene sequencing. 4 
Segregation of the mutation checked by Sanger sequencing. Black symbol = affected. Mutant 5 
allele in red. 6 
7 
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 2 
Supplementary Figure 3 : Rare damaging variants enriched in 3 
EPHB4. Averaged allele frequencies of rare non-synonymous tolerated (aggregation scores: 0 - 0.49) 4 
and damaging (aggregation scores: 0.5 – 1) variants within EPHB4 and RASA1 calculated for Caucasians 5 
in our study group (n=359; 79.6%) and in the ExAC database (n=33,370; 55%). To evaluate genetic burden, 6 
a “2-sample test for equality of proportions with continuity correction” was performed. Significant burden 7 
observed for EPHB4 (***p-value < 0.0001) and not significant for RASA1 (p-value = 0.257).  8 
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 1 
Filters used 
 
CM-13-HO-II-6A  
10 affected 
patients 
Total number of variants 
 
57018 761385 
NSV, SSV and indels 
 
11367 132057 
NOT in dbSNP and 1000G Database 
 
382 3162 
NOT in internal Database of 450 unrelated exomes 
 
316 2124 
Consensus prediction ≥ 6  41 760 
Regarding the 2 linked loci: 
 
 
     Variants 
 
3 27 
     Shared variants in affected sibling pair CM-90  
 
- 4 
     Shared variants in affected sibling pair CM-433  
 
- 8 
     Genes with variants in CM-13, CM-90 and CM-433  
 
1 1 
 
Number of other families with a variant in gene above  
 
 
- 2  (CM-291, CM-297) 
Number of distinct variants in gene above 
 
1 3 
 
Shared gene  
 
 
EPHB4 EPHB4 
 
NSV = Non-synonymous variants; SSV = Splice-site variants; Indels = Insertions/Deletions; 
Consensus_prediction ≥ 6; Functional predictions retrieved from dbNSFP4.1 (damaging in SIFT, deleterious 
in LRT, high or medium in Mutation Assessor, damaging in Fathmm, disease-causing in Mutation Taster, and 
a score > 0.5 in Polyphen2). 
 
Supplementary Table 1: Variant prioritization strategy used 2 
for whole exome sequencing data.  3 
 4 
Prioritization strategy of variants detected by whole exome sequencing. Successive numbers 5 
correspond to variants that met each criterion. Data shown for combined analysis for one CM-13-6 
9 
 
HO family member (II-6A) (left column) and for 8 other families, two of which had 2 patients 1 
sequenced (right column). For mutations, see Table 1. 2 
